<DOC>
	<DOCNO>NCT02108262</DOCNO>
	<brief_summary>This multicenter randomize , double-blind , placebo-controlled , parallel-group , dose-ranging phase 2b study investigate hepatic renal safety tolerability multiple dose administration two dose level CSL112 compare placebo subject acute myocardial infarction ( AMI ) .</brief_summary>
	<brief_title>A Phase 2b Study CSL112 Subjects With Acute Myocardial Infarction .</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>Men woman , least 18 year age , evidence myocardial necrosis clinical setting consistent type I ( spontaneous ) acute myocardial infarction ( AMI ) , last week . Ongoing hemodynamic instability Evidence hepatobiliary disease Evidence chronic kidney disease ( CKD ) ( Stage III , IV , V ) , define moderate severe renal impairment subject receive dialysis Evidence unstable renal function History acute kidney injury previous exposure intravenous contrast agent . Known history allergy , hypersensitivity deficiency CSL112 components Other severe comorbid condition , concurrent medication , issue render subject unsuitable participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>